A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms GEMPAX
- 17 Jan 2024 Primary endpoint has not been met. (Overall Survival), as per Results published in the Journal of Clinical Oncology
- 17 Jan 2024 Results published in the Journal of Clinical Oncology
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress